Findings

What do systematic reviews say?

165 questions · 172 findings · 79 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 39 · 22.7%GRADE not reported 8 · 4.7%Very low 51 · 29.7%Low 51 · 29.7%Moderate 14 · 8.1%High 9 · 5.2%

Intervention not reported

All‐cause mortality

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Social network interventions to support cardiac rehabilitation and secondary prevention in the management of people… 2023 · Cochrane Headline outcomes only
RR 0.75 [0.49, 1.13]
6 studies · 3093 participants
Low

Sildenafil vs Placebo or no active treatment

All‐cause mortality · pregnant women with fetal growth restriction

Sildenafil citrate showed no clear difference in all‐cause mortality compared with placebo or no therapy (moderate certainty).

1 finding from 1 review

Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
RR 1.01 [0.8, 1.27]
5 studies · 516 participants
Moderate

Sildenafil vs IV nitroglycerin

All‐cause mortality · pregnant women with fetal growth restriction

1 finding from 1 review

Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Tadalafil vs Placebo or no active treatment

All‐cause mortality · pregnant women with fetal growth restriction

Tadalafil showed no clear difference in all‐cause mortality compared with placebo or no therapy (low certainty).

1 finding from 1 review

Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
RR 0.2 [0.02, 1.6]
1 study · 87 participants
Low

Nitroglycerin vs Placebo or no active treatment

All‐cause mortality · pregnant women with fetal growth restriction

1 finding from 1 review

Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Low molecular weight heparin vs no prophylaxis

All‐cause mortality ( · adults undergoing KA

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1978 participants
GRADE not reported

Heparin vs pentasaccharide

All‐cause mortality · people undergoing bariatric surgery

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 198 participants
Very low

Heparin started before vs after the surgical procedure

All‐cause mortality · people undergoing bariatric surgery

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

IPC plus pharmacological prophylaxis vs mechanical prophylaxis alone

All‐cause mortality · people undergoing bariatric surgery

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

Higher‐dose heparin vs standard‐dose heparin

All‐cause mortality · people undergoing bariatric surgery

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 597 participants
Low

Remote monitoring plus usual care vs usual care

Mortality (all‐cause) · patients with chronic obstructive pulmonary disease

It is very uncertain whether remote monitoring plus usual care changes mortality (all‐cause) compared with usual care (very low certainty).

1 finding from 1 review

Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease… 2021 · Cochrane Headline outcomes only
OR 0.99 [0.62, 1.58]
7 studies · 927 participants
Very low

Remote monitoring vs usual care

Mortality (all‐cause) · patients with chronic obstructive pulmonary disease

It is very uncertain whether remote monitoring changes mortality (all‐cause) compared with usual care (very low certainty).

1 finding from 1 review

Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease… 2021 · Cochrane Headline outcomes only
OR 0.68 [0.37, 1.25]
6 studies · 798 participants
Very low

Transfusions continued vs transfusions halted

All‐cause mortality · prevention of SCI in people with SCD and normalised TCD velocities

It is very uncertain whether transfusions continued changes all‐cause mortality compared with transfusions halted (very low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
Peto OR 8 [0.16, 404.12]
1 study · 79 participants
Very low

Long‐term red cell transfusion vs usual care

All‐cause mortality · prevention of SCI in people with SCD and normal TCD velocities

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 196 participants
Low

Hydroxyurea vs RBC transfusion

All‐cause mortality · prevention of SCI in people with SCD who have not had a stroke (primary prevention)

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Hydroxyurea vs RBC transfusion

All‐cause mortality · prevention of SCI in people with SCD who had a stroke (secondary prevention)

It is very uncertain whether hydroxyurea changes all‐cause mortality compared with RBC transfusion (very low certainty).

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
OR 1.02 [0.06, 16.41]
1 study · 133 participants
Very low

Long‐term red cell transfusion vs usual care

All‐cause mortality · prevention of SCI in people with SCD and abnormal TCD velocities

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Very low

Multidisciplinary disease management programmes vs usual care

All‐cause mortality · adults with heart failure

Multidisciplinary disease management programmes probably leads to lower all‐cause mortality compared with usual care (moderate certainty).

1 finding from 1 review

Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
RR 0.67 [0.54, 0.83]
8 studies · 1764 participants
Moderate

Case management vs usual care

All‐cause mortality · adults with heart failure

Case management may leads to lower all‐cause mortality compared with usual care (low certainty).

1 finding from 1 review

Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
RR 0.78 [0.68, 0.9]
26 studies · 6903 participants
Low

Intervention not reported

All‐cause mortality · newborn infants at risk of gastrointestinal bleeding

It is very uncertain whether the intervention changes all‐cause mortality (very low certainty).

1 finding from 1 review

Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants 2019 · Cochrane Headline outcomes only
RR 2.42 [0.7, 8.38]
1 study · 53 participants
Very low